MedTrace Logo

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain

NCT02508337 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 309

Last updated 2017-01-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the clinical efficacy and safety of XG-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain following cataract surgery.

Conditions

Interventions

DRUG

XG-102

Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery

DRUG

Placebo

Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery

Sponsors & Collaborators

  • Xigen SA

    lead INDUSTRY

Principal Investigators

  • Juli Chalifour · ORA, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-01-31
Completion
2016-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02508337 on ClinicalTrials.gov